Cingulate Inc. (CING) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Kansas City, KS, United States. El CEO actual es Shane J. Schaffer.
CING tiene fecha de IPO 2021-12-08, 13 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $29.15M.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
